China Pharma Holdings (CPHI) is a small-cap Chinese generic pharmaceutical manufacturer with declining revenues and ongoing losses that experienced extreme volatility on July 15, 2026, surging over 70-100% intraday amid unusual trading activity with no company-identified catalysts. [Fact: Based on market data as of July 15, 2026]
As of July 15, 2026 (intraday, highly volatile):
Interpretation: This appears to be a short-term speculative surge or possible short squeeze in a low-float penny stock; long-term trend remains downward.
Uncertainty: Exact real-time price varies by source and timing; data snapshots from multiple financial platforms show rapid changes.
Fact: NYSE American contacted the company regarding unusual activity; company issued PR stating it knows of no events explaining the trading. Source
| Period | Return | Notes |
|---|---|---|
| YTD | ~9% (mixed reports; some negative) | Data inconsistency across sources; volatile period |
| 1-Year | -67.5% | Significant decline |
| 5-Year | ~-99.8% | Near total loss from peaks |
| 52-Week Range | $0.38 - $2.03 | Wide range typical of microcap |
Interpretation: Poor historical performance reflects operational challenges in a competitive Chinese pharma market; recent spike is anomalous and likely unsustainable without fundamentals.
Historical Data (Yahoo) | Performance Overview
| Metric | Value | Change/Notes |
|---|---|---|
| Revenue (TTM) | ~$3.99M - $4.14M | Down ~8.5% YoY [Fact] |
| Gross Profit / Margin | ~$290K / low or negative | Challenging margins |
| Net Income (TTM) | -$3.19M to -$3.55M | Losses narrowing slightly YoY in some reports |
| EPS (TTM) | -$0.36 to -$0.54 | Negative |
| Employees | 215 | |
| Shares Outstanding | ~40.5M | Potential dilution risk |
Fact: Fiscal year ends Dec 31; recent 10-K delayed (Form 12b-25 filed). Company focuses on GMP-certified generic drugs for high-incidence diseases in China.
Interpretation: Revenue contraction and persistent losses indicate operational difficulties; limited scale compared to industry peers.
Uncertainty / Limitations: Financials based on latest available TTM data (pre-full 2025 10-K); assumptions include standard US GAAP reporting; no dividend history.
| Metric | Value | Notes |
|---|---|---|
| Consensus Rating | N/A | No active analyst coverage |
| Price Target | N/A | None available |
| Number of Analysts | 0 | Typical for microcap with low liquidity |
Fact: No Wall Street analyst ratings or forecasts from major firms (e.g., MarketBeat, TipRanks show N/A).
Interpretation: Lack of coverage reflects small size, limited investor interest, and potential risks in Chinese regulatory/operational environment.
Uncertainty: Ratings could emerge with improved filings or news; current data limited to technical analysis on platforms like TradingView (mixed buy/sell signals).
Fact: Broad distribution in major Chinese cities/provinces; no specific major named customers disclosed in public filings.
Limitations: Detailed customer concentration or contracts not publicly detailed; typical for Chinese pharma with domestic focus.
| Competitor | Notes |
|---|---|
| Other Chinese generic manufacturers (e.g., smaller players or state-linked firms like Sinopharm subsidiaries) | Direct competition in generics market |
| International generics (e.g., Teva, Mylan equivalents in China) | Price competition in domestic market |
| Platform/event organizers (note: unrelated CPhI trade shows) | Search noise; not direct business competitors |
Interpretation: Operates in highly competitive, price-sensitive Chinese generics space with regulatory and quality pressures.
Limitations: Specific peer financial comparisons limited due to lack of direct listed analogs; public data sparse.
Yahoo Profile (Industry: Drug Manufacturers—Specialty & Generic)
China Pharma Holdings, Inc. develops, manufactures, and markets generic pharmaceutical products for human use in the People's Republic of China. Key therapeutic areas include central nervous system (CNS), cerebral-cardiovascular, anti-infection/respiratory, digestive diseases, and others. Business model emphasizes cost-effective, high-margin generics supported by GMP-certified facilities.
Fact: Wholly-owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd. in Haikou; ~215 employees.
Full Profile | Official Website
Fact: Public since early 2000s; CUSIP 16941T104 (older) or similar.
Data Limitations & Assumptions: All information compiled from publicly available web sources as of July 15, 2026. Stock prices are real-time volatile and may differ by platform/exchange delay. Financials are TTM approximations from reported data; full audited 2025 results pending. No investment advice; microcap stocks like CPHI carry high risk of illiquidity, dilution, and regulatory issues in China. Verify with primary sources (SEC, company IR). Competitors/customers inferred from industry context due to limited disclosures.